News

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of May.

Employment contracts can have enormous financial and career consequences, yet many clinicians review them too casually before signing.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.

Neal Bhatia, MD, describes a protocol spanning antihistamine pretreatment, in-room talk anesthesia, and post-procedure skin care to improve tolerability of photodynamic therapy.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

Learn how community events, like the recent Walk Under the Sun event, help turn sunscreen into a daily habit, explain hidden UV exposure, and debunk viral tanning myths.

Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.

This review of the latest dermatological studies includes insights on methylsulfonylmethane in dermatology, the use of ultrasound in cutaneous mastocytoma, AI-augmented morphometric reporting for aesthetic treatments, and more.

Maryanne Makredes Senna, MD, reviews early-onset efficacy, favorable tolerability, and high rates of patient-reported improvement associated with extended-release oral minoxidil data.

Explore evidence-backed nutricosmetics and hormone-aware nutrition for women’s skin and hair—plus what to know about collagen and dosing.

Among more than 1700 patients enrolled in the long-term extension study, the majority transitioned from a moderate to severe AD phenotype at baseline to a mild phenotype within 12 weeks, with that shift maintained through 2 years.

Dermatologists are increasingly integrating AI into clinical workflows, though many still use it primarily as a search tool rather than a true care-support system.

The fixed-dose adapalene 0.1% and benzoyl peroxide 2.5% topical OTC gel broadens nonprescription access to a combination topical regimen that has been used as a prescription product for more than 15 years.

Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.

Prospective data presented at ASLMS by Isabella Camacho-Hubbard, MD, shows Stellar M22 XPL Glide boosts photodamage results, speeds treatments, avoids striping, and maintains safety.

Phase 3 data presented at AAD 2026 showed that amlitelimab significantly improved skin clearance and disease severity in patients aged 12 years and older with moderate to severe atopic dermatitis.

The annual AK awareness campaigns spotlight hats, sun protection, and regular skin checks to catch actinic keratosis early and prevent skin cancer.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Elizabeth Buzney, MD, outlines the clinical hallmarks that separate erythropoietic protoporphyria from other photosensitivity disorders, starting with what clinicians won't see on exam.

Matthew Zirwas, MD, rethinks AD as environmentally acquired barrier dysfunction, sharing psychodermatology itch strategies and highlighting patient-centered communication.

The SWF Clinical Care Network now includes 27 validated US sites assessed objectively for multidisciplinary capacity across dermatology, neurology, ophthalmology, mental health, and transitional care.

Oral therapies at AAD 2026 are closing the efficacy gap with biologics, with two TYK2 inhibitors and an oral IL-23 peptide each delivering clearance rates once thought possible only with injectables.

Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.

Kathleen Moe, MD, discusses why operational dysfunction, not medicine itself, is driving physician exhaustion in dermatology and beyond.

Rapid GLP-1 weight loss can age the face—a new paper reviews multimodal nonsurgical fixes with fillers, Botox, devices, and skin care for natural balance.

Phase 3 SELVA and phase 2 TOIVA data show Qtorin rapamycin met primary end points for microcystic lymphatic and cutaneous venous malformations.

The growing success of IL-17–targeted therapies suggests that remission may become a realistic future goal for many patients living with hidradenitis suppurativa.

Epicutis’ Hydrobiome Serum targets post-procedure barrier repair, while CEO Max Stock explains physician-guided care and biotech’s microbiome future.

Neal Bhatia, MD, outlines the clinical rationale for incorporating photodynamic therapy into skin cancer treatment algorithms, from field cancerization management to emerging applications in superficial basal cell carcinoma.